You have access
Improved inhibitory and ADMET properties of blebbistatin derivatives indicate that blebbistatin scaffold is ideal for drug development targeting myosin-2
Máté Gyimesi, Anna Á. Rauscher, Sharad Kumar Suthar, Kamirán Á. Hamow, Kinga Oravecz, István Lőrincz, Zsolt Borhegyi, Máté T. Déri, Ádám F. Kiss, Katalin Monostory, Pál Tamás Szabó, Suman Nag, Ivan Tomasic, Jacob Krans, Patrick J. Tierney, Mihály Kovács, László Kornya and András Málnási-Csizmadia
Journal of Pharmacology and Experimental Therapeutics January 19, 2021, JPET-AR-2020-000167; DOI: https://doi.org/10.1124/jpet.120.000167
